NGM Bio Outlines 2022 Strategic Priorities Across Its Portfolio of Clinical-Stage Oncology, Retinal and Liver and Metabolic Programs

NEXT STORY
Adial Pharmaceuticals to Present at the H.C. Wainwright BioConnect 2022 Conference
PREV STORY
Junshi Biosciences and Coherus Expand Immuno-Oncology Collaboration to Include TIGIT-Targeted Antibody
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Medivir licenses rights to MIV-802 to Trek Therapeutics

Stockholm/Cambridge, Massachusetts — Medivir AB (Nasdaq Stockholm: MVIR) and Trek Therapeutics (TREKtx) today announced ...

author_avatar
NASDAQ Market News

Foamix Reports Second Quarter 2016 Financial Results and Provides Business Update

REHOVOT, Israel, Aug. 10, 2016 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX) (“Foamix Pharmaceuticals” or ...

author_avatar
NASDAQ Market News

Taconic Biosciences Launches TruIMPORT™ Importation Solution

author_avatar
NASDAQ Market News